• Source : Press Release
  • Date : 2021-11-12
  • Companies : Roche

Roche Diagnostics Korea Hosts mRNA Technology Meeting for APAC Region

Roche Diagnostics Korea's CustomBiotech team hosted an online meeting for researchers and companies developing mRNA technology on Thursday.

Dr. Ajay Singh at Gennova Biopharmaceuticals in India explains the advantages and future of mRNA vaccines and shares Gennova's Covid-19 mRNA vaccine development cases at an online meeting held by Roche Diagnostics Korea's CustomBiotech team on Thursday.

More than 200 experts in charge of research and development (R&D) and production of mRNA technology shared their understanding of mRNA-based technology and future directions at the meeting targeting the Asia-Pacific region.

India's Gennova Biopharmaceuticals Dr. Ajay Singh, Singapore's Nanyang Technological University Professor Cho Nam-joon, Korea University Professor Kim Yoon-ki lectured about the future of mRNA technology beyond Covid-19.

Professor Kim introduced the study of mRNA stabilization for therapeutics and understanding of degradation process during the first session.

Dr. Ajay explained the advantages and future of mRNA vaccines and shared the cases of Gennova's Covid-19 mRNA vaccine development.

Professor Cho shared the understandings of lipid nanoparticle technology (LNP), which can be used as a carrier for various drugs, and the direction of LNP technology development.

Dr. Bhawana Poudel-Bochmann, CustomBiotech team's International Product Manager, presented Roche Diagnostics' role as a raw material supplier for mRNA vaccines. "Roche manufactures all products meeting GMP standards, supporting companies that develop products in a large and small capacity in uniformed quality," she said,

Bhawana added that Roche's support would contribute to solving difficulties facing companies with the development and supply of vaccines.

"Recently, technology related to mRNA vaccines has attracted more attention than ever due to the Covid-19 pandemic," Roche Diagnostics Korea CEO Kit Tang said. "We will contribute to the development of local companies mRNA vaccines and therapeutics with timely supply of raw materials as a major supplier."